Literature DB >> 11257013

Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.

D F Sahm1, J A Karlowsky, L J Kelly, I A Critchley, M E Jones, C Thornsberry, Y Mauriz, J Kahn.   

Abstract

Although changing patterns in antimicrobial resistance in Streptococcus pneumoniae have prompted several surveillance initiatives in recent years, the frequency with which these studies are needed has not been addressed. To approach this issue, the extent to which resistance patterns change over a 1-year period was examined. In this study we analyzed S. pneumoniae antimicrobial susceptibility results produced in our laboratory with isolates obtained over 2 consecutive years (1997-1998 and 1998-1999) from the same 96 institutions distributed throughout the United States. Comparison of results revealed increases in resistant percentages for all antimicrobial agents studied except vancomycin. For four of the agents tested (penicillin, cefuroxime, trimethoprim-sulfamethoxazole, and levofloxacin), the increases were statistically significant (P < 0.05). Resistance to the fluoroquinolone remained low in both years (0.1 and 0.6%, respectively); in contrast, resistance to macrolides was consistently greater than 20%, and resistance to trimethoprim-sulfamethoxazole increased from 13.3 to 27.3%. Multidrug resistance, concurrent resistance to three or more antimicrobials of different chemical classes, also increased significantly between years, from 5.9 to 11%. The most prevalent phenotype was resistance to penicillin, azithromycin (representative macrolide), and trimethoprim-sulfamethoxazole. Multidrug-resistant phenotypes that included fluoroquinolone resistance were uncommon; however, two phenotypes that included fluoroquinolone resistance not found in 1997-1998 were encountered in 1998-1999. This longitudinal surveillance study of resistance in S. pneumoniae revealed that significant changes do occur in just a single year and supports the need for surveillance at least on an annual basis, if not continuously.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257013      PMCID: PMC90422          DOI: 10.1128/AAC.45.4.1037-1042.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

Authors:  C Thornsberry; M E Jones; M L Hickey; Y Mauriz; J Kahn; D F Sahm
Journal:  J Antimicrob Chemother       Date:  1999-12       Impact factor: 5.790

3.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae.

Authors:  M C McEllistrem; J E Stout; L H Harrison
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 5.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

6.  Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study.

Authors:  C Thornsberry; D F Sahm
Journal:  Chemotherapy       Date:  2000       Impact factor: 2.544

7.  Novel expansions of the gene encoding dihydropteroate synthase in trimethoprim-sulfamethoxazole-resistant Streptococcus pneumoniae.

Authors:  T Padayachee; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use.

Authors:  K Waites; K Rand; S Jenkins; B Yangco; E Brookings; D Gaskins; J Lewis; K Halkias
Journal:  Diagn Microbiol Infect Dis       Date:  1994-03       Impact factor: 2.803

9.  Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong.

Authors:  K M Kam; K Y Luey; S M Fung; P P Yiu; T J Harden; M M Cheung
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.

Authors:  G V Doern; A B Brueggemann; H Huynh; E Wingert
Journal:  Emerg Infect Dis       Date:  1999 Nov-Dec       Impact factor: 6.883

View more
  31 in total

1.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.

Authors:  J A Karlowsky; L Nealy; D F Sahm; C Thornsberry; M E Jones
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002.

Authors:  Jean-Winoc Decousser; Patrick Pina; Florent Viguier; Franc Picot; Patrice Courvalin; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillance.

Authors:  S Nunes; R Sá-Leão; J Carriço; C R Alves; R Mato; A Brito Avô; J Saldanha; J S Almeida; I Santos Sanches; H de Lencastre
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Properties of novel international drug-resistant pneumococcal clones identified in day-care centers of Lisbon, Portugal.

Authors:  Natacha G Sousa; Raquel Sá-Leão; M Inês Crisóstomo; Carla Simas; Sónia Nunes; Nelson Frazão; João A Carriço; Rosario Mato; Ilda Santos-Sanches; Hermínia de Lencastre
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Nelson L Jumbe; Arnold Louie; Michael H Miller; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

7.  In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.

Authors:  Laura Lawrence; Paul Danese; Joe DeVito; Francois Franceschi; Joyce Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

8.  Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.

Authors:  Todd A Davies; Alan Evangelista; Sharon Pfleger; Karen Bush; Daniel F Sahm; Raul Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 9.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.